About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.
Benefits of Adjuvant RT for Early Breast Cancer Limited to First 10 Years
Adjuvant radiotherapy (RT) for early breast cancer protected against ipsilateral recurrence for 10 years after treatment but not thereafter, according to long-term follow-up from a